CepTor's Drug Development Initiatives Substantiated by New England Journal of Medicine Article; Article Implicates Calpain in Duchenne Muscular Dystrophy and Other Neuromuscular and Neurodegenerative Diseases.

HUNT VALLEY, Md. -- CepTor Corporation, Inc. (OTC BB: CEPO), a development-stage biopharmaceutical company focusing on cell targeted therapeutic products for neuromuscular and neurodegenerative diseases, noted that the recent New England Journal of Medicine (June 9, 2005 issue) lead review article, "Mechanisms of Disease: Calpains and Disease" implicates calpain as a primary protease that, when up-regulated, initiates accelerated tissue breakdown in several neuromuscular and neurodegenerative diseases. This includes Duchenne muscular dystrophy (DMD), a genetic disease which affects 1 out of every 3,500 male children rendering them wheelchair dependent by about the age of 12 with death common in late adolescence. The article substantiates CepTor's drug development initiatives of MYODUR to treat DMD by targeting a leupeptin analogue into the muscle cells to inhibit calpain in order to preserve muscle.

According to Norman Barton, M.D., Ph.D., Executive Vice President and Chief Medical Officer of CepTor, "This is a very important article as it is further validation that our research and development strategy for MYODUR is on the right track. We have been focused on calpain inhibition for DMD, and as a result of extensive research we believe that we have developed a unique, proprietary, safe and efficient, targeted calpain inhibitor." Dr. Barton continued, "Currently, we are preparing to file an investigational new drug application and move MYODUR into phase I/II clinical trials for DMD in children with this devastating disease."

ABOUT MYODUR:

MYODUR targets muscle cells by using a carnitine carrier molecule and inhibits calpain by attaching a leupeptin analogue onto the carrier. Leupeptin has been studied extensively in a variety of animal models and was shown to be an effective means of slowing or delaying muscle wasting. Carnitine is a compound present in skeletal muscle involved in the transfer of fatty acids across mitochondrial membranes. CepTor's technology uses the carnitine carrier molecule to direct the leupeptin analogue into targeted cells where it inhibits the up-regulation of calpain. Therefore, by targeting a calpain inhibitor to muscle cells, it is believed that MYODUR will prevent the degradation and promote the preservation of functional muscle.

ABOUT CALPAIN:

Calpain exists in every cell of the body and is a protease that degrades cellular proteins naturally in a normal metabolic process. When calpain is abnormally up regulated, the accelerated degradation process breaks down cells and tissues faster than they can be restored, resulting in several serious neuromuscular and neurodegenerative diseases.

About CepTor

CepTor Corporation is a development-stage biopharmaceutical company engaged in the discovery, development, and commercialization of proprietary, cell-targeted therapeutic products for the treatment of neuromuscular and neurodegenerative diseases with a focus on orphan diseases. The Company's mission is to increase the quality and quantity of life of people suffering with these diseases. An orphan disease is defined in the United States as a serious or life-threatening disease that affects less than 200,000 people and for which no definitive therapy currently exists. CepTor Corporation seeks to create an efficient orphan drug platform by taking advantage of the legislative, regulatory and commercial opportunities common to these rare diseases. CepTor's primary efforts are currently being focused on moving its lead product, MYODUR, into phase I/II clinical trials for Duchenne's muscular dystrophy. The Company's broad platform technology also includes the development of products for multiple sclerosis, retinal degeneration and epilepsy.

This news release contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our pharmaceutical collaborator's ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third party reimbursement.